Review Papers Claim by Claim

 Quick Explanation Copied

 Long Explanation

What the review establishes

Jang, Redon, Thakur, Bahta, and Aladjem (Experimental & Molecular Medicine, Oct 2, 2020) argue that all eight CRL families — not just the canonical SCF/CRL1 — drive cell cycle progression by ubiquitinating CDK inhibitors (p21/p27/p57 via SKP2, CDT2, DCAF11, LRR1, SPSB1), cyclins D/E/A/B, CDC25 phosphatases, origin licensing factors (CDC6, CDT1, MCM2-7), and mitotic regulators (Aurora kinases, PLK1, CENP-A, survivin, katanin) Jang et al. 2020 review full text. The authors are NIH/NCI intramural and Chungbuk National University funded and declare no conflicts of interest.

Cross talk with APC/C

The review's strongest synthesis is its integration of CRL and APC/C wiring: SKP2 is an APC/C-CDH1 substrate in G1; EMI1 blocks APC/C throughout S phase until CRL1-βTrCP destroys it in G2; CRL1-Cyclin F and APC/C-CDH1 form a reciprocal feedback loop; CRL4-RBBP7-mediated BUB3 degradation releases the spindle checkpoint CRL-APC/C cross talk section.

Critical assessment

Strengths: exhaustive Table 1 (128 references), clear mechanistic schematics, and a forward-looking therapeutic thesis — RepID-mediated CRL4 chromatin recruitment as a drug target, and molecular glues (lenalidomide, thalidomide) as substrate-receptor-specific degraders. Complementary mechanistic work supports the degradation framework: APC/C assembles branched K11/K48 chains that enhance proteasomal degradation of mitotic substrates Branched ubiquitin chain study, and structural work resolved distinct K48 versus branched-chain recognition modes by the 26S proteasome 26S proteasome chain-topology cryo-EM.

Limitations the authors partially acknowledge: as a narrative review it has literature selection bias; many Table 1 entries lack identified substrate receptors ("?" entries for CRL3/4/7/9); several claims rest on overexpression or single cell lines; model-organism findings (yeast, Drosophila, Xenopus) are extrapolated to humans; and neddylation inhibitors (pevonedistat) are non-specific, which the authors concede Therapeutic perspective section. Notably underexplored: tissue-specific redundancy among CRLs, quantified degradation kinetics, and whether CUL7/CUL9 cell cycle roles are direct or indirect.

Supporting primary evidence reinforces the SKP2 axis central to the review: genetic susceptibility to rat hepatocarcinogenesis tracks with SKP2/CKS1-mediated posttranslational degradation of p21/p27/p57/p130, with human HCC Ki-67 inversely correlating with CKI protein but not mRNA levels SKP2/CKS1 hepatocarcinogenesis study.

 BGPT Paper Review

Study Novelty

A well-organized synthesis, but most CRL1/CRL4 cell cycle biology was established before 2020; the relatively novel elements are the exhaustive CRL7/CRL9 coverage and RepID-mediated CRL4 chromatin recruitment framing.

Scientific Quality

Rigorous, heavily referenced (128 refs), no conflicts, clearly structured; docked for narrative-review selection bias, several substrate receptors left unidentified, and reliance on cross-species extrapolation.

Study Generality

Cell cycle control via ubiquitin ligases is a fundamental, broadly applicable framework spanning cancer, replication licensing, and mitosis across eukaryotes.

Study Usefulness

Comprehensive Table 1 and cross-talk maps are directly actionable for cancer drug discovery (neddylation inhibitors, molecular glues, recruiter-targeting strategies).

Study Reproducibility

Reviews are not experiments; no primary data or methods; reproducibility limited to whether cited primary findings replicate, some of which rest on single cell lines.

Explanatory Depth

Mechanistic depth is high: receptor-level specificity, phosphorylation-dependence, subcellular localization logic, PCNA platforming, and feedback-loop topology are all explained.